Recent Aβ-immunotherapy trials demonstrated that removing aggregated Aβ from the brains of symptomatic patients can slow progression of Alzheimer’s disease. This perspective analyzes different immunoprevention strategies by integrating findings from clinical trials with mechanistic insights from preclinical disease models.Recent Aβ-immunotherapy trials demonstrated that removing aggregated Aβ from the brains of symptomatic patients can slow progression of Alzheimer’s disease. This perspective analyzes different immunoprevention strategies by integrating findings from clinical trials with mechanistic insights from preclinical disease models.Mathias Jucker, Lary C. Walkerhttps://www.cell.com/cell/fulltext/S0092-8674(23)00910-8?rss=yeshttp://www.cell.com/cell/inpress.rssCellCell RSS feed.Wireless News CampaignSeptember 20, 2023

Powered by WPeMatico